Early Phase 1 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to sign a consent form and attend follow-up appointments.
- People aged 50 or older.
- People who have been diagnosed with active wet age-related macular degeneration (AMD) causing abnormal blood vessel growth under the retina.
- People whose vision in the study eye falls within a specific range — not too strong and not too weak (confirm with trial site for exact vision level).
- People who have received at least 2 eye injections for this condition in the 6 months before screening, and whose eye showed a meaningful improvement from those injections.
- People who are able to use effective contraception from the start of screening until the last follow-up visit, if there is any possibility of pregnancy for themselves or their partner.
Who may not be able to join:
- People whose abnormal blood vessel growth or retinal swelling is caused by a condition other than wet AMD.
- People who have retinal detachment, eye inflammation, uncontrolled glaucoma, or any other condition in the study eye that would prevent vision from improving.
- People who have had a heart attack, unstable chest pain, heart bypass or stenting procedure, stroke, or mini-stroke in the past 6 months.
- People with uncontrolled high blood pressure, based on blood pressure readings above a certain level (confirm with trial site).
- People with uncontrolled diabetes, based on a blood sugar control test result taken within 28 days before screening being above a certain level (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment; Dose Limiting Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.